Pendal Group’s Amedisys AMED Stock Holding History

Pendal Group’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,120	Closed	-$222K	–	439
2020 Q2	$222K	Buy	+1,120	New	+$209K	﹤0.01%	398

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pendal Group's AMED Position: Q3 2020 in Review

Pendal Group sold out of Amedisys (AMED) in Q3 2020, closing a stake of 1,120 shares — an estimated $222K sold.

Pendal Group first reported a position in AMED in Q2 2020 and held it in 1 quarter. The position peaked at $222K in Q2 2020. 397 funds tracked by Wall St. Rank hold AMED as of Q3 2020.

Pendal Group reported no remaining Amedisys position as of Q3 2020 after selling out during the quarter.
Pendal Group sold 1,120 Amedisys shares in Q3 2020, an estimated $222K.
Pendal Group first reported a position in Amedisys in Q2 2020 and held it in 1 quarter.
Pendal Group's Amedisys position peaked at $222K in Q2 2020.
397 funds tracked by Wall St. Rank held Amedisys as of Q3 2020.

Based on Pendal Group's 13F filing for Q3 2020, filed 2 Nov 2020.